Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA clears Idera psoriasis therapy trial
IMO-3100 is a dual antagonist of Toll-like receptor (TLR) 7 and TLR9, which is indicated as a therapy for autoimmune and inflammatory diseases. In July 2011, the company
IMO-3100 is a dual antagonist of Toll-like receptor (TLR) 7 and TLR9, which is indicated as a therapy for autoimmune and inflammatory diseases. In July 2011, the company
The facility aims to provide personalized medicine for different types of cancer, based on the latest genetic research findings and advances in synthetic organic chemistry. H3 Biomedicine intends
Ficlatuzumab is Aveo’s novel HGF inhibitory antibody that is currently in phase II clinical development to treat non-small cell lung cancer (NSCLC). Under the terms of the contract,
The solutions include cloud-based Veeva CRM and iRep. According to the company, the cloud solution will bring many business and operational benefits including faster deployment, better flexibility to
Ferrosan Consumer Health’s business provides dietary supplements and lifestyle product. Pfizer Consumer Healthcare president Paul Sturman said they have taken an important step by adding Ferrosan’s brands to
CK-2017357, a fast skeletal muscle troponin activator, increases skeletal muscle force in response to neuronal input, reducing the degree of muscle fatigue. The Phase II, double-blind placebo-controlled trial
Both the companies have finalized a one-year extension of the deal, under which Safecor Health will continue to provide unit-dose and bar-coded medication repackaging services to members and
NX002 is a peptide derived from the naturally occurring growth factor AMP-18, which has been shown to stimulate the growth of epithelial cells and to promote mucosal wound
Some of the proposed activities of PAE include activating patients, their families, relatives and caregivers through the availability of information and access to pain diagnosis and management, as
Conditas will represent the Melbourne and Shanghai based company as its agent for business development and sales of services in the US. The Conditas Group Jr. founder and